Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys

Psychopharmacology

Volumn 144, Issue 3, 1999, Pages 234-238

  Callahan, Michael J ^a  

^a PFIZER INC   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Milameline (CI 979 RU 35 926); Rapid information processing; Rhesus monkey; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; MILAMELINE; MUSCARINIC AGENT; SCOPOLAMINE; TACRINE;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; TASK PERFORMANCE;

ANIMALS; CHOLINESTERASE INHIBITORS; DIHYDROPYRIDINES; DRUG INTERACTIONS; FEMALE; MACACA MULATTA; MALE; MUSCARINIC AGONISTS; OXIMES; PSYCHOMOTOR PERFORMANCE; SCOPOLAMINE; TACRINE;

EID: 0033031828     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050998     Document Type: Article

References (28)

1. Bachevalier J, Landis LS, Walker LC, Brickson M, Mishkin M, Price DL, Cork LC (1991) Aged monkeys exhibit behavioral deficits indicative of widespread cerebral dysfunction. Neurobiol Aging 12:99-111
2. Bartus RT (1978) Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methlyphenidate with scopolamine. Pharmacol Biochem Behav 9:833-836
3. Bartus RT, Johnson HR (1976) Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol Biochem Behav 5:39-46
4. Bartus RT, Fleming D, Johnson HR (1978) Aging in the rhesus monkey: debilitating effects on short-term memory. J Gerontol 33:858-871
5. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM (1988) Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26:685-700
6. Brown K, Warburton DM (1971) Attenuation of stimulus sensitivity by scopolamine. Psychon Sci 22:297-298
7. Buccafusco JJ, Jackson WJ, Terry AV Jr (1992) Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by primates. Life Sci 51:PL 7-12
8. Callahan MJ, Kinsora JJ, Harbaugh RE, Reeder TM, Davis RE (1993) Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys. Neurobiol Aging 14:147-151
9. Callaway E (1984) Human information-processing: some effects of methylphenidate, age, and scopolamine. Biol Psychiatry 19:649-662
10. Callaway E, Halliday R, Naylor H, Brandeis D (1991) Clonidine and scopolamine: differences and similarities in how they change human information processing. Prog Neuropsychopharmacol Biol Psychiatry 15:497-502
11. Carey GJ, Costall B, Domeney AM, Gerrard PA, Jones DN, Naylor RJ, Tyers MB (1992) Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacol Biochem Behav 42:75-83
12. Duka T, Redemann B, Mager T, Voet B (1993) Scopolamine as a pharmacological tool to study memory processes; application of a cognition enhancer. Neurosci Abstr 19:1235
13. Flood JF, Smith GE, Cherkin A (1983) Memory retention: potentiation of cholinergic drug combinations in mice. Neurobiol Aging 4:37-43
14. Giacobini E (1997) Cholinesterase inhibitors do more than inhibit cholinesterase. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhauser, Boston, pp 187-204
15. Knapp MJ, Knopman DS, Solman PR, Pendlebury WW, Davis CS, Gracon SI, Tacrine Study Group (1994) A 30 week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271:985-991
16. M'Harzi M, Palou A-M, Oberlander C, Barzaghi F (1995) Antagonism of scopolamine-induced impairments in rats by the muscarinic agonist RU 35 926 (CI-979). Pharmacol Biochem Behav 51:119-124
17. Moss MB, Rosene DL, Peters A (1988) Effects of aging on visual recognition memory in the rhesus monkey. Neurobiol Aging 9:495-502
18. Murray TK, Cross AJ, Green AR (1991) Reversal by tetrahydroaminoacridine of scopolamine-induced memory and performance deficits in rats. Psychopharmacology 105:134-136
19. 1 agonist AF-102B. Jpn J Pharmacol 48:502-506
20. Parrott AC (1986) The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6 and 1.2 mg) upon psychological performance. Psychopharmacology 89:347-354
21. Rapp PR, Amaral DG (1989) Evidence for task-dependent memory dysfunction in the aged monkey. J Neurosci 9:3568-3576
22. Rupniak NMJ, Steventon MJ, Field MJ, Jennings CA, Iversen SD (1989) Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 99:189-195
23. Rupniak NMJ, Tye SJ, Field MJ (1997) Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology 131:406-410
24. Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JR, Price DL (1994) Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14:167-186
25. Walker LC, Kitt CA, Struble RG, Wagster MV, Price DL (1988) The neural basis of memory decline in aged monkeys. Neurobiol Aging 9:657-666
26. Wesnes K, Warburton DM (1983) Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology 9:154-157
27. Wesnes K, Warburton DM (1984) Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82:147-150
28. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237-1239